Process for the continuous manufacture of a polyisobutylene based transdermal patch

US11911522B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11911522-B2
Application numberUS-202016859313-A
CountryUS
Kind codeB2
Filing dateApr 27, 2020
Priority dateJul 21, 2009
Publication dateFeb 27, 2024
Grant dateFeb 27, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.

First claim

Opening claim text (preview).

The invention claimed is: 1. A continuous process for the production of an adhesive composition comprising: a) pre-processing a non-granulated high molecular weight polyisobutylene (HMW PIB) having a molecular weight ranging from about 200,000 g/mol to about 800,000 g/mol in a single-screw extruder to form a bulk BMW PIB material, wherein said bulk BMW PIB material is in a compressed, continuous feed form; b) extruding said bulk HMW PIB material in an extruding apparatus, wherein said HMW PIB is extruded; c) simultaneously extruding said extruded HMW PIB with low molecular weight polyisobutylene (LMW PIB) in said extruding apparatus to produce high shear so as to form an extruded melt, wherein a ratio of the amount of HMW PIB to LMW PIB in said melt ranges from about 50:50 to about 70:30; d) adding an active pharmaceutical ingredient (API) to said extruded melt to produce an extruded API/PIB melt; and e) discharging said extruded API/PIB melt to a die to form said adhesive composition, wherein said adhesive composition comprises about 93% to about 97% PIB and about 3% to about 7% API. 2. The process of claim 1 , wherein said single screw extruder is heated to a temperature between about 85° F. and about 500° F. 3. The process of claim 1 , wherein said high molecular weight polyisobutylene has a molecular weight ranging from about 425,000 g/mol to about 800,000 g/mol. 4. The process of claim 1 , wherein said high molecular weight polyisobutylene has a molecular weight ranging from about 200,000 g/mol to about 425,000 g/mol. 5. The process of claim 1 , wherein said BMW PIB and said LMW PIB are simultaneously extruded in a twin-screw extruder. 6. The process of claim 1 , wherein said low molecular weight polyisobutylene has a molecular weight ranging from about 35,000 g/mol to about 100,000 g/mol. 7. The process of claim 1 , wherein said low molecular weight polyisobutylene has a molecular weight ranging from about 36,000 g/mol to about 75,000 g/mol. 8. The process of claim 1 , wherein said low molecular weight polyisobutylene is heated to a temperature between about 65° F. and about 500° F. 9. The process of claim 1 , wherein said active pharmaceutical ingredient is selected from the group consisting of an opioid receptor antagonist, anesthetics, local anesthetics, anti-asthmatics, anti-inflammatory substances, opiates, bronchodilators, analgesics, anti-hypertensive drugs, hormones, contraceptives, anti-nauseants, anti-histamines, stimulants, anti-anginal drugs, opiate receptor agonists, dopamine agonists, anticholinergics, neuromuscular drugs, anabolic drugs, anti-emetics, decongestants, vasoconstrictors, sedatives, psychotropics, diuretics, vasodilators, hypnotics, anti-pyretics, and anti-spasmodics. 10. The process of claim 1 , wherein said active pharmaceutical ingredient is selected from the group consisting of lidocaine, piroxicam, fentanyl, sufentanyl, albuterol, buprenorphine, clonidine, diclofenac, estradiol, ethinyl estradiol, granisetron, ketoprofen, loratadine, memantine, methylphenidate, naltrexone, nicotine, nitroglycerin, norelgestromin, oxybutynin, risperidone, rivastigmine, rotigotine, scopolamine, selegiline, testosterone, desloratadine, dexmethylphenidate, and tulobuterol. 11. The process of claim 1 , further comprising adding one or more additives to said API/PIB melt. 12. The process of claim 1 , further comprising laminating said adhesive composition between a backing layer and a release liner to produce a transdermal delivery device. 13. The process of claim 1 , wherein the HMW PIB is free from fillers. 14. The process of claim 1 , wherein the API is lidocaine, and said adhesive composition comprises lidocaine in an amount of about 5%. 15. A continuous process for the production of an adhesive composition comprising: a) pre-processing a non-granulated high molecular weight polyisobutylene (HMW PIB) having a molecular weight ranging from about 425,000 g/mol to about 800,000 g/mol in a single-screw extruder to form a bulk HMW PIB material, wherein said bulk HMW PIB material is in a compressed, continuous feed form; b) extruding said bulk HMW PIB material having a molecular weight ranging from about 425,000 g/mol to about 800,000 g/mol in a twin-screw extruding apparatus, wherein said HMW PIB is extruded; c) simultaneously extruding said extruded HMW PIB with low molecular weight polyisobutylene (LMW PIB) in said extruding apparatus to produce high shear so as to form an extruded melt; wherein said LMW PIB has a molecular weight ranging from about 36,000 g/mol to about 75,000 g/mol; and wherein a ratio of the amount of HMW PIB to LMW PIB in said melt ranges from about 50:50 to about 70:30; d) adding an active pharmaceutical ingredient to said extruded melt to produce an extruded API/PIB melt; and e) discharging said extruded API/PIB melt to a die to form said adhesive composition, wherein said adhesive composition comprises about 93% to about 97% PIB and about 3% to about 7% API. 16. The process of claim 15 , wherein said LMW PIB has a number average molecular weight of about 51,000 and said API is lidocaine.

Assignees

Inventors

Classifications

  • A61K9/7053Primary

    obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene · CPC title

  • C09J123/22Primary

    Copolymers of isobutene; Butyl rubber {; Homo- or copolymers of other iso-olefines} · CPC title

  • Copolymers of isobutene; Butyl rubber; Homopolymers or copolymers of other iso-olefins · CPC title

  • containing two or more polymers of the same C08L -group · CPC title

  • Homopolymers or copolymers of unsaturated hydrocarbons; Derivatives thereof · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11911522B2 cover?
The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.
Who is the assignee on this patent?
Mylan Inc
What technology area does this patent fall under?
Primary CPC classification A61K9/7053. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).